Extavia

A new interferon beta-1b available for the management of multiple sclerosis.

Extavia (interferon beta-1b) is indicated for the treatment of:

  • Patients with a single demyelinating event with an active inflammatory process severe enough to require iv corticosteroids if alternative diagnoses have been excluded and they are at high risk of developing multiple sclerosis.
  • Relapsing-remitting multiple sclerosis in patients who have had at least two relapses in the preceding two years.
  • Secondary progressive multiple sclerosis with active disease evidenced by relapses.

Interferons are an established treatment option for multiple sclerosis. The exact mechanism of action is unknown although they are throught to work through immunomodulatory effects.

View Extavia drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

PHE issues coronavirus guidance for primary care

PHE issues coronavirus guidance for primary care

Public Health England (PHE) has issued guidance for...

HPV infections fall dramatically but researchers say vaccine efficacy is 'uncertain'

HPV infections fall dramatically but researchers say vaccine efficacy is 'uncertain'

Cancer-causing HPV16 and 18 infections are now 'extremely...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: Adcal D3 Dissolve, Diamox SR, flumetasone/clioquinol,...